Submissions

CHPA supports improving the compendial test methods and establishing product standards for levels of elemental impurities which can provide an additional measure of safety for OTC products.

Letter to Dr. Shawn Dressman regarding U.S. Pharmacopeia's Stimuli article: USP's Monographs in Support of FDA's OTC Monograph System: Modernization Opportunities.

CHPA welcomes the opportunity to comment on the above captioned request published in the January 18, 2013 Federal Register.

CHPA takes this opportunity to respectfully express our opposition to proposed Ordinance #02013-1063, a measure proposing to ban the sale of products containing triclosan in the City of Chicago.

CHPA takes this opportunity to respectfully express our opposition to SF 1166, a measure proposing to ban the sale of products containing triclosan in Minnesota.

This report builds upon current insights with findings from a new survey which examines two important stakeholder groups and analyzes what drives these groups’ use and trust in OTC medicines.

CHPA supports FDA's goals of reducing medical errors, simplifying device use information into data systems, identifying devices with adverse events, facilitating recall efficiency, and focusing communication.

CHPA candidate submission for consideration to serve as the non-voting industry representative on the FDA Pediatric Advisory Committee.